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Abstract
Background: Home-based management of malaria (HMM) is promoted as a major strategy to improve prompt
delivery of effective malaria treatment in Africa. HMM involves presumptively treating febrile children with pre-
packaged antimalarial drugs distributed by members of the community. HMM has been implemented in several
African countries, and artemisinin-based combination therapies (ACTs) will likely be introduced into these
programmes on a wide scale.
Case presentations: The published literature was searched for studies that evaluated the health impact of
community- and home-based treatment for malaria in Africa. Criteria for inclusion were: 1) the intervention
consisted of antimalarial treatment administered presumptively for febrile illness; 2) the treatment was
administered by local community members who had no formal education in health care; 3) measured outcomes
included specific health indicators such as malaria morbidity (incidence, severity, parasite rates) and/or mortality;
and 4) the study was conducted in Africa. Of 1,069 potentially relevant publications identified, only six studies,
carried out over 18 years, were identified as meeting inclusion criteria. Heterogeneity of the evaluations, including
variability in study design, precluded meta-analysis.
Discussion and evaluation: All trials evaluated presumptive treatment with chloroquine and were conducted
in rural areas, and most were done in settings with seasonal malaria transmission. Conclusions regarding the
impact of HMM on morbidity and mortality endpoints were mixed. Two studies showed no health impact, while
another showed a decrease in malaria prevalence and incidence, but no impact on mortality. One study in Burkina
Faso suggested that HMM decreased the proportion of severe malaria cases, while another study from the same
country showed a decrease in the risk of progression to severe malaria. Of the four studies with mortality
endpoints only one from Ethiopia showed a positive impact, with a reduction in the under-5 mortality rate of
40.6% (95% CI 29.2 – 50.6).
Conclusion: Currently the evidence base for HMM in Africa, particularly regarding use of ACTs, is narrow and
priorities for further research are discussed. To optimize treatment and maximize health benefits, drug regimens
and delivery strategies in HMM programmes may need to be tailored to local conditions. Additional research
could help guide programme development, policy decision-making, and implementation.
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Introduction
Malaria remains one of the major public health problems
worldwide, and of the estimated 400 to 900 million epi-
sodes of fever occurring yearly in African children, proba-
bly about half are due to malaria, resulting in over one
million deaths [1-3]. However, the proportion of deaths
due to malaria varies widely with malaria transmission
[4,5]. Prompt treatment with effective antimalarial ther-
apy is essential and African leaders have committed to
ensuring that 80% of malaria episodes are adequately
treated within 24 hours of onset of symptoms by 2010 [6].
However, treatment of malaria is challenged by inade-
quate health-care infrastructure in many parts of Africa
[7,8]. Health facilities are often resource-limited, and
access to care may be limited by distance, fees, inadequate
staffing, and lack of essential medicines [9-11]. The direct
and especially indirect costs of seeking health care from
formal facilities may be substantial, providing a major
barrier for many households [12]. Thus, febrile illnesses
are commonly treated at home, frequently with drugs pur-
chased from shops [13]. It is estimated that fewer than
20% of children with malaria in endemic areas are treated
in formal health-care settings [1].
To improve access to antimalarials, the World Health
Organization (WHO) is promoting home-based manage-
ment of malaria (HMM) as a major strategy for Africa
[14]. HMM involves presumptively treating febrile chil-
dren at or near home with antimalarial drugs distributed
by trained members of the community [14,15]. Commu-
nity distributors provide medications and educate pri-
mary caregivers about treatment of malaria,
administration of antimalarial drugs, and recognition of
severe illness. Emphasis on prompt treatment and distri-
bution of pre-packaged antimalarials are strengths of the
HMM strategy [16,17]. However, there are potential
downsides to presumptive treatment at home. Use of anti-
malarials to treat all febrile episodes, even if administered
correctly, may delay treatment of other illnesses [18]. In
addition, unnecessary over-treatment with antimalarials
could promote drug resistance [19,20] and is likely to
have substantial economic consequences [21].
Recently, antimalarial treatment policies in Africa have
undergone a major transition; most countries have
adopted artemisinin combination therapies (ACTs) as
first-line treatment for uncomplicated malaria [22].
Whether ACTs can be successfully incorporated into
HMM and used safely and effectively at home is a critical
question [23,24]. The cost of implementing ACTs in sub-
Saharan Africa according to current prescribing practices
has been estimated at US$ 1.6 – 3.4 billion per year, and
the cost-effectiveness of deploying ACTs in HMM remains
uncertain [21,23]. Quoted data supporting HMM policy
are limited, and the impact of HMM on malaria-associ-
ated morbidity and mortality has not been fully estab-
lished in most settings. The ideal regimen for use in HMM
programmes is also not clear, and may vary by setting.
This paper presents a review of published studies evaluat-
ing the health impact of community- and home-based
treatment for malaria in Africa. The aim of this review is to
summarize the current evidence base for HMM, and to
identify areas where further research could guide imple-
mentation of HMM in Africa.
Case presentations
A search of PubMed was conducted on 10 June 2007 using
the keyword strategy in Table 1. All abstracts identified in
the search were reviewed for potential relevance; if
abstracts appeared to satisfy the stated criteria, the full text
was obtained. Bibliographies of relevant publications and
studies referred to in the gray literature (WHO and
national reports) were also reviewed. Inclusion criteria for
studies reviewed were as follows: 1) the intervention eval-
uated consisted of antimalarial treatment administered
presumptively for febrile illness; 2) the treatment was
administered by local community members who had no
formal education in health care; 3) measured outcomes
included specific health indicators such as malaria mor-
bidity (incidence, severity) and/or mortality, and/or
malariometric indices including parasite rates, hemo-
globin or packed cell volume (PCV), and spleen rates; and
4) the study was conducted in Africa.
One thousand sixty-nine (1,069) potentially relevant arti-
cles were identified, most of which were not related to
community-based diagnosis or treatment of malaria. Of
the remainder, the following were excluded: a study that
evaluated treatment in schools [25], as well as studies that
measured only process indicators [26-28], assessed only
changes in care-seeking and referral patterns [18,28], or
evaluated only feasibility and acceptability [29-32]. A
study from Niger, published in 1985, reported differences
in malaria morbidity between villages with and without
village health workers who provided both chemoprophy-
laxis and presumptive treatment with chloroquine (CQ),
but there were no data distinguishing the effects of treat-
ment from those of chemoprophylaxis [33]. Only one
Table 1: Search strategya
Keyword Searches
Home management of malaria (HMM);
Home-based management of malaria;
Home-based management of fever (HBMF);
Malaria AND community-based, community-directed, community 
participation, community care, community health volunteer, 
community health worker, community health aide, village health 
worker, village health volunteer, volunteer, volunteer health worker, 
lay health worker, birth attendant, midwife, traditional healer
a PubMed search conducted 10 June 2007Malaria Journal 2007, 6:134 http://www.malariajournal.com/content/6/1/134
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study, also published in 1985, was excluded on the basis
of being conducted outside Africa; this study reported on
the health impact of a village-based programme for pre-
sumptive antimalarial treatment of fever in Papua New
Guinea [34]. Six studies that met all inclusion criteria were
identified (Figure 1).
Six studies that involved presumptive administration of
antimalarial treatment at or near the household level and
that met the search criteria were identified (Table 2 and
Figure 2) [35-42]. One project in Kenya [35,36] and
another in The Gambia [37,38] were described in multi-
ple papers.
Kenya 1981–1983
This community-based project was conducted in a hyper-
to holo-endemic area near Lake Victoria [35,36,43,44]. All
households were registered, and the community was
divided into three areas, two interventional, and one con-
trol. Community health workers (CHWs) were trained to
give CQ free of charge "to every person who came for
treatment saying they had malaria," and to refer ill
patients. Each household was revisited at six to nine
month intervals and information on births, deaths, and
migration was recorded. Biannual surveys were also con-
ducted in randomly selected villages to assess parasitemia
and antimalarial antibodies.
Despite high utilization, presumptive treatment with CQ
was found to have no impact on malaria-specific or over-
all mortality. Further, there was no change in parasite
prevalence or serologic markers. The authors attributed
the lack of effect to the high level of presumptive treat-
ment with CQ in the community prior to the onset of the
programme.
The Gambia 1982–1987
A community-based programme in an area with seasonal
transmission was conducted in 1982–85 [37], with fol-
low-up assessments in 1986–87 [38]. Forty-one villages
were stratified according to population size. Larger vil-
lages were selected to participate in a national primary
health care scheme, which began in 1983, while the
smaller villages served as a control group. The CHWs
received health-care training, including presumptive treat-
ment of malaria with CQ, over a 6-week period. An initial
stock of basic medicines was provided, and CHWs were
expected to purchase new supplies using funds from drug
Sites of published studies on the health impact of home- and  community-based treatment for malaria in Africa Figure 2
Sites of published studies on the health impact of home- and 
community-based treatment for malaria in Africa. Two stud-
ies were conducted in Burkina Faso. The map, adapted from 
MARA: Mapping Malaria Risk in Africa [69], shows seasonal-
ity of malaria transmission in months per year, as in the key.
Kenya
The Gambia
Burkina Faso
Ethiopia
Zaire (DRC)
Categorization of published articles identified by the search  strategy Figure 1
Categorization of published articles identified by the search 
strategy.
Not primarily related to diagnosis and treatment 
of fever/malaria symptoms at or near the home 
n = 943 
Documented existing care-seeking and 
home fever diagnosis/treatment practices 
n = 69 
Total publications identified 
by search strategy 
n = 1069 
Included in the review 
n = 8 
(Reporting on 6 
separate studies) 
Discussed logistics or other issues related to 
community-based health program 
n = 24 
Editorial or opinion piece on HMM/HBMF 
n = 4
Addressed economic aspects of 
home fever/malaria management 
n = 2 
Assessed only community perceptions or 
acceptability of HMM strategy 
n = 5 
Assessed only impact on treatment-
seeking or correctness of treatment 
n = 13 
Was not conducted in Africa 
n = 1Malaria Journal 2007, 6:134 http://www.malariajournal.com/content/6/1/134
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sales. A group of CHWs also distributed either pyrimeth-
amine/dapsone chemoprophylaxis or placebo every two
weeks to children aged 3–59 months, randomly allocating
children by household. The study compared two strategies
for malaria control: presumptive treatment of malaria
Table 2: Characteristics of published studies of home- and community-based treatment for malaria in Africaa
Location Epidemiology Drug distribution Incentive Outcomes 
measured
Results
Kenya
1981–83
(Spencer et al, 1987a, 
1987b)
• Rural
• Hyper- to holo-
endemic
• CHWs provided 
presumptive CQ 
treatment for free
• Volunteer CHWs 
supported by the 
village
• Overall and malaria-
specific mortality
• Birth and fertility 
rates
• Parasite rates
No obvious effect of 
providing CQ for 
treatment of malaria 
on mortality, fertility, 
or parasite rates
The Gambia
1982–87
(Greenwood et al, 
1988; Menon et al, 
1990)
• Rural
• Seasonal 
transmission
• CHWs sold CQ for 
presumptive 
treatment
• Volunteer CHWs 
supported by the 
village
• Overall and malaria-
related mortality
• Frequency of clinical 
malaria
• Packed cell volume, 
parasite rates, 
splenomegaly
Treatment alone had 
no significant effect on 
morbidity and 
mortality from malaria
Zaire (DRC)
1985–87
(Delacollette et al, 
1996)
• Rural
• Meso-endemic
• Continuous 
transmission with 
seasonal fluctuations
• CHWs sold CQ at 
cost for presumptive 
treatment
• CHWs received 
"symbolic monetary 
reward"
• Malaria morbidity 
and mortality
• Parasitological 
indices
• Proportion of fever 
episodes receiving 
antimalarial treatment, 
proportion receiving 
treatment at home, 
and source of 
treatment
No impact on malaria 
mortality, but two-
fold reduction in 
malaria prevalence 
and incidence
Burkina Faso 1994–95
(Pagnoni et al, 1997)
• Rural
• Seasonal 
transmission
• Mothers trained to 
recognize illness and 
make decision to treat
• CHWs sold pre-
packaged CQ for 
presumptive 
treatment
• CHWs kept 0.6 US 
cents for each package 
sold
• Proportion of 
under-5 malaria cases 
recorded as severe in 
health centres
• Mothers' care-
seeking practices
• Availability and use 
of drugs at peripheral 
level, community 
awareness of 
educational messages
The proportion of 
severe cases 
decreased in the first 
year of the program; 
in the second year, 
the proportion 
decreased only in 
health facilities with 
drug coverage ≥50%
Ethiopia
1996–98
(Kidane and Morrow, 
2000)
• Rural
• Seasonal 
transmission
• Mother 
coordinators provided 
presumptive CQ 
treatment for free
• None mentioned • Malaria-related 
mortality in children 
under age 5 years
Intervention 
associated with 40.6% 
reduction in overall 
under-5 mortality 
(95% CI 29.2–50.6, p 
< 0.003)
Burkina Faso
1998–99
(Sirima et al, 2003)
• Rural
• Hyperendemic
• Seasonal 
transmission
• Mothers trained to 
recognize illness and 
make decision to treat
• CHWs sold pre-
packaged CQ for 
presumptive 
treatment
• Drugs sold with 10% 
incentive margin for 
CHW
• Incentive provided 
to some drug store 
managers
• Proportion of 
malaria cases 
progressing to severe 
(as reported by 
mothers in annual 
cross-sectional 
surveys)
• Proportion of cases 
receiving correct dose 
of CQ
Risk of progression to 
severe malaria lower 
in children treated 
promptly with pre-
packaged CQ (5%) 
than not (11%) (RR 
0.47, 95% CI 0.37–
0.60, p < 0.0001)
aCHW = community health worker; CQ = chloroquine; RR = risk ratioMalaria Journal 2007, 6:134 http://www.malariajournal.com/content/6/1/134
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with CQ alone or combined with pyrimethamine/dap-
sone prophylaxis.
In the initial evaluation, presumptive treatment of fever
with CQ was found to have no impact on morbidity or
mortality. However, in children aged 1–4 years, pyrimeth-
amine/dapsone prophylaxis in addition to CQ treatment
led to a significant decrease in mortality and incidence of
clinical malaria, a fall in spleen and parasite rates, and an
increase in packed cell volume. Similar findings were
observed in the follow-up evaluation, conducted 3–4
years later. The authors noted that CQ resistance, first
described in The Gambia one year after this study was
completed, was unlikely to account for the lack of effect of
presumptive CQ treatment. Instead, the ineffectiveness of
the programme was attributed to the volunteer status of
the CHWs and their limited availability.
Zaire (Democratic Republic of Congo) 1985–1987
This study was conducted in a meso-endemic area on the
western shore of Lake Kivu [39]. Two regions were chosen,
one for the intervention, and the other for the control.
"Literate volunteers" were selected by the community to
serve as CHWs, and were trained to administer "timely"
presumptive treatment with CQ.
The intervention was associated with a decrease in malaria
morbidity: a two-fold reduction in mean malaria preva-
lence and incidence, and a five- to six-fold decrease in par-
asitological indices were observed. However, there was no
difference in malaria mortality, and 24% of fever cases
remained untreated at the end of the observation period.
The authors attributed the lack of mortality impact to the
relatively small sample size (total population 28,000),
and limitations of verbal autopsies for determining
malaria-related deaths. They also suggested improved
availability of CQ, rather than the specific mechanism of
its delivery, may have accounted for some of the observed
morbidity benefit. In addition, a number of problems
concerning the relationship of the CHWs to the health
care system and the community were observed, leading
the authors to question the sustainability of a community-
based programme with dedicated CHWs. "The non-com-
prehensiveness of the CHWs' care and their ambiguous
position in the health care system created problems that
compromise the sustainability of the intervention."
Burkina Faso 1994–1995
This study was carried out in one province in north-west-
ern Burkina Faso with seasonal malaria transmission [40].
The primary aim of the study was to assess the impact of
community-based provision of prompt antimalarial treat-
ment on the risk of progression to severe disease. The
intervention involved teaching mothers to recognize
malaria episodes and providing pre-packaged CQ through
CHWs. A "core group" of mothers and CHWs received
training from local nurses in the diagnosis and treatment
of uncomplicated malaria, and were expected to train
other mothers in the village. Emphasis was placed on
entrusting mothers with the decision to treat their chil-
dren. Pre-packaged CQ was supplied to health dispensa-
ries, and the CHWs sold full treatments under a cost-
recovery scheme. Pre- and post- intervention data were
collected to allow for historical comparisons. National
Health Information System (NHIS) data on the number
of patients with "uncomplicated" or "severe" malaria pre-
senting at dispensaries were used to evaluate the impact of
the intervention. Of note, the intervention was transferred
from the national to provincial level midway through the
study, which affected the distribution of the drugs and
supervision of the programme.
A decrease in the proportion of severe malaria cases
recorded in health centre log books was noted during
1994, as compared to the four preceding years. In 1994,
258 of 6725 (3.8%) malaria cases were documented as
severe, compared to 704 of 14314 (4.9%) of cases in
1990–1993 (reported p = 0.0005). In 1995, the results
were stratified by drug availability at the health centres. In
health centres with a drug coverage index of ≥ 50% (47%
of dispensaries) the proportion of severe cases was lower
than in previous years. However, in facilities with poor
drug availability, the proportion of severe cases was
higher than in 1990–93. The authors comment on several
limitations of the study including the use of NHIS data for
the primary endpoint and comparison to historical con-
trols. Dispensary records of severe malaria typically corre-
spond with cerebral malaria only, limiting detection of
other forms of complicated malaria. In addition, nurses
recording the malaria cases at the health facilities were
also involved in implementing the programme, which
may have influenced recording of malaria cases. However,
the authors concluded that the results of this study con-
firmed the feasibility and affordability of community-
based presumptive treatment, and suggested a morbidity
benefit. Empowering mothers as decision-makers for
diagnosis and treatment, and the cost-recovery scheme of
the programme, were considered to be strengths of the
intervention.
Ethiopia 1996–1998
This trial examined the effect of "teaching mothers to
promptly provide antimalarials to their sick children at
home," as compared to health facility-based treatment, on
under-5 mortality [41]. The study was conducted in two
districts of Tigray, a region with mostly seasonal malaria.
The 24 tabias (clusters of villages) with the highest
malaria morbidity were paired by their under-5 childhood
mortality rates. One tabia from each pair was randomly
assigned to the intervention, the other to the control.Malaria Journal 2007, 6:134 http://www.malariajournal.com/content/6/1/134
Page 6 of 10
(page number not for citation purposes)
"Mother coordinators" in all tabias were trained to keep
records of local births and deaths and to refer sick chil-
dren, and were responsible for tracking drug supplies at
the local health centre. In the intervention tabias, mother
coordinators were additionally trained to teach other local
mothers to recognize symptoms of malaria, and to give
prompt CQ treatment. CQ was supplied to the mother
coordinators in the intervention group for distribution to
all households, and the mothers were responsible for
replenishing the drug supply.
This widely-cited study found a reduction in the under-5
mortality rate of 40.6% (95% CI 29.2 – 50.6). In the inter-
vention group, 190 of 6383 children died (29.8 per
1000), compared to 366 of 7294 (50.2 per 1000) in the
control group (p < 0.003). The authors did note that the
Tigray region was involved in a civil war from 1974 until
1991; after years of war and isolation, local characteristics
were seen as possible reasons for the success of the pro-
gramme. The authors emphasize that "it is important to
recognize the special biological and sociopolitical factors
of the Tigray study that may limit applicability in other
parts of Africa such as the presence of chloroquine-sensi-
tive falciparum malaria, a disciplined population accus-
tomed to coping for themselves, strong community
solidarity, and no alternative income opportunities for
the mother coordinators."
Burkina Faso 1998–1999
This observational study was conducted in south-eastern
Burkina Faso, an area with hyper-endemic seasonal
malaria [42]. A "core group of opinion leaders," mostly
older mothers, and CHWs were trained in diagnosis of
malaria, referral of cases, and treatment with pre-packaged
CQ and aspirin. Health centre drug store managers were
trained to package age-specific doses for sale to CHWs,
who in turn sold the drugs to local mothers, at a price
allowing for full cost-recovery of the drugs plus a 10%
incentive margin. Outcomes for children treated promptly
(within 24 hours) with pre-packaged antimalarials were
compared to those who did not receive such treatment.
The outcome of "severe malaria" was defined as an epi-
sode of fever followed by convulsions or loss of con-
sciousness, as reported by mothers.
Of 1806 children receiving prompt treatment with pre-
packaged CQ, 93 (5%) progressed to severe malaria, com-
pared to 153 of 1396 (11%) of children who did not
receive this treatment (risk ratio 0.47, 95% CI 0.37 – 0.60,
p < 0.0001). The authors address the possible impact of
non-differential misclassification, recall bias, lack of para-
sitological confirmation of disease, and confounding fac-
tors on their findings, concluding that these were unlikely
to affect their positive results. The authors noted that this
study only provides evidence on risk of progression to cer-
ebral malaria, not other clinical forms of malaria, includ-
ing severe anemia.
Discussion and evaluation
Prompt treatment with effective antimalarials is a corner-
stone of malaria control in Africa. HMM has the potential
to improve treatment delivery and decrease malaria-asso-
ciated morbidity and mortality. However, the HMM strat-
egy is a major undertaking, and its implementation
should be based on sound evidence of public health ben-
efit. To assess the current evidence base for HMM, a review
was conducted of published studies that evaluated the
health impact of community- and home-based treatment
for malaria in Africa. The six studies identified were con-
ducted in diverse epidemiological settings in five coun-
tries over a span of 18 years. Heterogeneity of the
evaluations, including variability in study design, pre-
cluded meta-analysis. All studies were conducted in rural
areas, and most were done in settings with seasonal
malaria transmission. Of the two trials conducted in per-
ennial transmission areas, one in Kenya showed no obvi-
ous effect of the intervention [35,36], while the other in
the Democratic Republic of Congo showed a decrease in
malaria morbidity but no impact on mortality [39]. All
studies evaluated presumptive treatment with CQ, and
only two studies (both in Burkina Faso) reported using
pre-packaged drugs, a key element of the HMM strategy;
critically, no data are available on use of ACTs or other
alternative therapies [45]. Of the four studies that
included mortality endpoints, only one showed a benefit
[41]. Data showing an impact of community-based pro-
grammes on malaria morbidity are also relatively sparse
with only one study showing a decrease in malaria preva-
lence and incidence [39], and one demonstrating a
decreased risk of progression to severe (essentially cere-
bral) malaria [42]. Thus, current evidence demonstrating
the health benefit of home- and community-based pre-
sumptive treatment of fever with antimalarials is limited,
and does not necessarily support widespread implemen-
tation of HMM.
The WHO has advocated scaling up home-based pro-
grammes in malaria-endemic countries, supported by the
positive results of the two most recent studies [14,41,42].
As of 2004, three countries in Africa (Eritrea, Ethiopia and
Uganda) were implementing the full HMM strategy with
a non-ACT regimen, while other countries were incorpo-
rating some components of the strategy [15]. In Uganda,
HMM was initiated with pre-packaged CQ + sulfadoxine-
pyrimethamine (Homapak), but artemether-lumefantrine
(AL) has recently been introduced in the HMM pro-
gramme in northern districts, and widespread introduc-
tion of AL is expected in the future. Although there are
plans to evaluate use of AL in HMM in Uganda, and a
community-based trial of AL is currently on-going inMalaria Journal 2007, 6:134 http://www.malariajournal.com/content/6/1/134
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Burkina Faso (Sirima, personal communication), cur-
rently there are no published data on use of ACTs in HMM
programmes.
Provision of ACTs in HMM could have substantial eco-
nomic and public health implications. Implementation of
home- or community-based programmes based on non-
ACT regimens (CQ or CQ plus sulfadoxine-pyrimeth-
amine) have been shown to be relatively affordable
[40,46], and a cost-effectiveness model found that pro-
vider training, community education and pre-packaging
of CQ compared favorably with other malaria control
measures [47]. The system costs of implementing HMM
are expected to be similar regardless of which regimen is
used; however, the cost of deploying ACTs in HMM will
certainly be higher than that of CQ. Although the effec-
tiveness of HMM with ACTs is likely to be greater than
with CQ, this has not been demonstrated. In addition,
further evaluation of the cost-effectiveness of HMM, par-
ticularly using ACTs, would be instructive. Deployment of
ACTs just within the public health sector already poses a
significant challenge to many countries due both to cost
and to limitations in the global supplies of artemisinin
compounds [48-50], and the costs and benefits of further
deployment of ACTs in HMM programmes should be
assessed.
Presumptive treatment of all childhood fevers in Africa
would greatly increase ACT demand and drug pressure,
even if just a proportion of fevers were actually treated. A
number of studies suggest that increased antimalarial use
speeds the emergence and spread of parasite resistance
[20,51-53]. Instead of deploying a single ACT regimen as
first-line treatment in both health facilities and HMM, use
of different regimens in different settings may be an alter-
native approach. Early modeling work suggests that using
more than one ACT in a region, e.g. administering differ-
ent ACTs in facilities and in HMM, may slow development
of resistance, although this theory requires further investi-
gation [54]. Poor patient adherence to treatment is also
likely to contribute to the development of parasite resist-
ance, through exposure of parasites to subtherapeutic
drug levels [55,56]. Use of pre-packaged drugs, as pro-
moted for HMM, has been shown to improve adherence
[16,17] which may deter parasite resistance. The impact of
widespread presumptive use of ACTs in HMM pro-
grammes on the development of drug resistance requires
further study.
Considering the available literature, how can future
research address the gaps in evidence, especially in the era
of ACTs? Evaluation of the impact of community-based
treatment on malaria-associated morbidity and mortality
in different epidemiologic settings, particularly areas with
perennial malaria transmission, would be useful to help
support wide-scale implementation of HMM. Additional
questions exist regarding the optimal regimen for HMM,
method of drug distribution and maintenance of supplies,
use of incentives, programme design in different social
settings (e.g. rural vs urban), safety risks, sustainability,
and cost-effectiveness. A recent WHO document provides
a detailed review of the implementation processes of
HMM studies conducted in Burkina Faso, Ghana, Nigeria
and Uganda, identifying "lessons learned" and challenges
for future programme planning [45]. Observations sum-
marized in this document can help to identify opportuni-
ties to improve existing HMM programmes and directions
for further research. In countries that plan to implement
HMM with ACTs, research could be closely linked to
implementation, for example by randomizing communi-
ties to HMM with ACTs in a phased design with a robust
impact assessment data collection system. Further, it will
be important to evaluate the impact of different models of
delivery of ACTs. For example, what is the added value of
HMM with ACTs in a setting where formal health care is
strengthened, minimizing medicine stock-outs and moti-
vating staff?
The question of payment of CHWs is an important issue:
financial compensation may provide incentive for CHWs
to provide consistent service, but payment may also dis-
rupt existing social patterns of reciprocity, and contribute
unnecessarily to the cost of the programme [57]. The
WHO recommends that CHW incentives and remunera-
tion should be agreed upon with the communities where
programmes are implemented [45]. The impact of CHWs,
and different compensation approaches, on local socioe-
conomic structures may be an interesting area for further
research. An additional challenge for community-based
programmes is the shift in social structures and malaria
epidemiology brought on by rapid urbanization in sub-
Saharan Africa [58,59]. Community health interventions
in rural areas may be more successful than in urban areas
with looser social ties. This effect has already been seen
with community-directed treatment for lymphatic filaria-
sis in Ghana, where the programme in urban areas was
affected by the "lack of closely knit community structure
and ... intense migration" [60]. Consideration of social
networks in urban areas will be necessary if successful
community-based health programmes are to be imple-
mented in cities, where an increasingly large percentage of
the African population lives.
Use of diagnostics to target therapy versus presumptive
treatment of fever is another important question. Empiric
treatment of fever with antimalarials is widely advocated
and practiced in Africa, although presumptive diagnosis
has been demonstrated in many settings to be highly inac-
curate [61-64]. Field evaluations of commercially availa-
ble rapid diagnostic tests (RDTs) for malaria have shownMalaria Journal 2007, 6:134 http://www.malariajournal.com/content/6/1/134
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that personnel with no formal training are able to satisfac-
torily prepare and interpret these tests [65,66]. RDTs may
prove useful in targeting treatment to patients most likely
to be suffering from malaria, and their adoption in African
HMM programmes should be studied. However, the suc-
cessful use of RDTs will require a significant cultural shift
in the way health workers deal with negative test results
[67,68].
Conclusion
Ideally, all children with malaria in Africa should be
treated promptly with effective antimalarials. Presumptive
treatment of febrile children with pre-packaged antimalar-
ials in HMM programmes is likely to increase delivery of
effective drugs, and improve the timing, adherence, and
dosing of treatment. Results from evaluations of commu-
nity acceptability and feasibility are encouraging, but fur-
ther study of health outcomes, including the impact on
morbidity and mortality, will provide stronger evidence to
support sustained implementation of community-based
interventions. Introduction of ACTs into HMM will
require substantial investment, and may divert funds from
other public health programmes and investment in health
facilities. Malaria epidemiology, drug resistance patterns,
health infrastructure, and societal structures vary widely
across Africa. The approach to drug delivery and treatment
will likely need to be tailored to local conditions. Further
evaluations of HMM and community-based delivery of
antimalarials will help to optimize treatment strategies
and maximize health benefits.
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